 The purpose of this study is to compare the efficacy and safety of Endostar Recombinant Human Endostatin combined with Docetaxel and single Docetaxel through multi-center, double-blinding, randomized controlled, phase IV clinical trial for NSCLC cases who have obvious progressive disease or intolerant adverse effects in first-line chemotherapy. 